Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Clinical Significance of Lung-RADS Category 3 Lesions in the National Lung Screening Trial.

About this Publication
Title
Clinical Significance of Lung-RADS Category 3 Lesions in the National Lung Screening Trial.
Pubmed ID
33722708 (View this publication on the PubMed website)
Digital Object Identifier
Publication
J Thorac Oncol. 2021 Mar 12
Authors
Han DH, Duan F, Wu Y, Goo JM, Kim HY, Patz EF
Affiliations
  • Department of Radiology, Duke University Health System, Durham, North Carolina; Present Address: Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Department of Biostatistics and Center for Statistical Sciences, Brown University School of Public Health, Providence, Rhode Island.
  • Department of Radiology, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Department of Radiology, Research Institute & Hospital, National Cancer Center, Goyang, Republic of Korea.
  • Department of Radiology, Duke University Health System, Durham, North Carolina; Department of Pharmacology and Cancer Biology, Duke University Health System, Durham, North Carolina. Electronic address: patz0002@mc.duke.edu.
Abstract

INTRODUCTION: To determine the clinical significance of CAT3 abnormalities and the necessity of a six-month follow-up CT. We also explored features associated with increased lung cancer risk.

METHODS: From the NLST database, we identified participants with CAT3 lesions at prevalence screen. Rates of lung cancer and lung cancer-specific deaths (LSD) were compared between those who underwent first follow-up CT before six months (Early Diagnostic Group, EDG) and those who underwent annual screening (Annual Diagnostic Group, ADG). We estimated the change in LSD if the 6-month-CT was eliminated. Regression analysis was performed to identify features associated with CAT3 participants who developed lung cancer.

RESULTS: 1763 CAT3s were identified (6.6% of all LDCT participants), with a total of 108 lung cancers (6.1 %) and 41 LSDs (2.3 %) over seven-year period. Rates of lung cancer (7.5 vs. 3.1 %) and LSD (4.0 vs. 1.0 %) were higher in EDG than in ADG. We estimated an increase in LSD of 0.6 % of all CAT3 participants (24.4 % of all LSDs) if the 6-month-CT was not performed. Multivariate regression analysis found increased age, emphysema, and a part-solid nodule >5 mm were associated with CAT3 participants who developed lung cancer.

CONCLUSIONS: CAT3 lesions are uncommon and eliminating the 6-month-CT would potentially increase LSD by 0.6% of all CAT3 patients. Age, emphysema, part-solid nodule >5 mm may be useful in risk prediction models to determine which CAT3 participants are more likely to develop lung cancer, and suggest which patients may need more intense follow-up.

Related CDAS Studies
Related CDAS Projects